Aldeyra Therapeutics Inc (NASDAQ: ALDX) on Monday, soared 10.99% from the previous trading day, before settling in for the closing price of $1.91. Within the past 52 weeks, ALDX’s price has moved between $1.14 and $7.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 16.10%. With a float of $57.98 million, this company’s outstanding shares have now reached $59.65 million.
Let’s look at the performance matrix of the company that is accounted for 9 employees. In terms of profitability, gross margin is 50.0%, operating margin of -24585.13%, and the pretax margin is -22840.7%.
Aldeyra Therapeutics Inc (ALDX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Aldeyra Therapeutics Inc is 2.90%, while institutional ownership is 55.52%. The most recent insider transaction that took place on Apr 03 ’25, was worth 4,828,000. In this transaction 10% Owner of this company sold 3,400,000 shares at a rate of $1.42, taking the stock ownership to the 5,875,851 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Chief Development Officer sold 16,041 for $4.74, making the entire transaction worth $75,975. This insider now owns 236,771 shares in total.
Aldeyra Therapeutics Inc (ALDX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.68% during the next five years compared to 15.99% growth over the previous five years of trading.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) Trading Performance Indicators
Aldeyra Therapeutics Inc (ALDX) is currently performing well based on its current performance indicators. A quick ratio of 5.48 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach 0.05 in one year’s time.
Technical Analysis of Aldeyra Therapeutics Inc (ALDX)
Aldeyra Therapeutics Inc (NASDAQ: ALDX) saw its 5-day average volume 2.41 million, a positive change from its year-to-date volume of 1.29 million. As of the previous 9 days, the stock’s Stochastic %D was 16.89%. Additionally, its Average True Range was 0.60.
During the past 100 days, Aldeyra Therapeutics Inc’s (ALDX) raw stochastic average was set at 16.17%, which indicates a significant decrease from 17.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 563.32% in the past 14 days, which was higher than the 227.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.5800, while its 200-day Moving Average is $5.1000. Nevertheless, the first resistance level for the watch stands at $2.2200 in the near term. At $2.3200, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.4600. If the price goes on to break the first support level at $1.9800, it is likely to go to the next support level at $1.8400. Assuming the price breaks the second support level, the third support level stands at $1.7400.
Aldeyra Therapeutics Inc (NASDAQ: ALDX) Key Stats
Market capitalization of the company is 126.59 million based on 59,709K outstanding shares. Right now, sales total 0 K and income totals -55,850 K. The company made 0 K in profit during its latest quarter, and -15,810 K in sales during its previous quarter.
